Tus Qd

# Tus Qd ## Overview Tus-QD is a prescription-strength antitussive/decongestant combination typically containing **Hydrocodone Polistirex** (opioid antitussive) and **Chlorpheniramine Polistirex** (antihistamine). The "Polistirex" formulation is an extended-release ion-exchange resin designed for 12-hour dosing. ## Primary Indications Symptomatic relief of cough and upper respiratory symptoms (e.g., rhinorrhea, sneezing) associated with the common cold or upper respiratory allergies. ## Adult Dosing * **Dosage:** 10 mL (containing 20 mg hydrocodone/8 mg chlorpheniramine) orally every 12 hours. * **Maximum:** Do not exceed 20 mL in a 24-hour period. ## Pediatric Dosing * **Children 6 to 12 years:** 5 mL orally every 12 hours. * **Maximum:** 10 mL in a 24-hour period. * *Note:* Use is generally not recommended in children under 6 years due to risk of respiratory depression and lack of safety data. ## Dose Adjustments * **Renal/Hepatic Impairment:** No specific guidelines available; use with extreme caution. Start at the lower end of the dosing range and monitor closely for sedation/toxicity. * **Elderly:** Use lowest effective dose; higher susceptibility to CNS depression and anticholinergic effects (urinary retention, confusion, constipation). ## Contraindications * Hypersensitivity to hydrocodone, chlorpheniramine, or any product components. * Concomitant use of MAO inhibitors (or within 14 days). * Known or suspected paralytic ileus. * Significant respiratory depression. ## Adverse Effects * **Common:** Drowsiness, sedation, dizziness, nausea, vomiting, constipation, dry mouth. * **Serious:** Respiratory depression, hypotension, urinary retention, serotonin syndrome (if combined with serotonergic agents), abuse/misuse potential. ## Key Drug Interactions * **CNS Depressants:** Alcohol, benzodiazepines, and other opioids significantly increase the risk of profound sedation and respiratory depression. * **Anticholinergics:** Additive effects leading to increased risk of urinary retention and severe constipation. * **Serotonergic Agents:** Increased risk of serotonin syndrome. * **CYP450 Inhibitors/Inducers:** Hydrocodone is metabolized by CYP3A4 and CYP2D6; inhibitors may increase plasma concentrations, potentially leading to opioid toxicity. ## Monitoring * Monitor for signs of respiratory depression (e.g., shallow breathing, cyanosis). * Assess for bowel function (constipation) and urinary retention, particularly in the elderly. * Evaluate mental status for confusion or excessive sedation. ## Clinical Pearls * **Shake well:** The suspension must be shaken thoroughly before each dose to ensure uniform medication concentration. * **Measurement:** Use an accurate dosing device (oral syringe or calibrated cup); household spoons are not accurate. * **Caution:** Because of the hydrocodone content, this medication is a **Schedule II Controlled Substance** and carries a high risk for addiction, abuse, and misuse. * **Alcohol:** Explicitly warn patients to avoid alcohol, as it can cause a rapid, potentially fatal release of the extended-release components. *** **Educational Disclaimer:** This information is for educational purposes only. Prescribing practices and clinical protocols vary by institution and jurisdiction. Always consult the latest FDA-approved package insert and current institutional guidelines before prescribing or administering medication.